Epithelial cells possess apical-basolateral polarity and form tight junctions (TJs) at the apical-lateral border, separating apical and basolateral membrane domains. The PAR3-aPKC-PAR6 complex plays a central role in TJ formation and apical domain development during tissue morphogenesis [1] [2] [3] [4] . Inactivation and overactivation of aPKC kinase activity disrupts membrane polarity [5] [6] [7] [8] . The mechanism that suppresses active aPKC is unknown. KIBRA, an upstream regulator of the Hippo pathway, regulates tissue size in Drosophila [9-11] and can bind to aPKC [12, 13] . However, the relationship between KIBRA and the PAR3-aPKC-PAR6 complex remains unknown. We report that KIBRA binds to the PAR3-aPKC-PAR6 complex and localizes at TJs and apical domains in epithelial tissues and cells. The knockdown of KIBRA causes expansion of the apical domain in MDCK three-dimensional cysts and suppresses the formation of apical-containing vacuoles through enhanced de novo apical exocytosis. These phenotypes are restored by inhibition of aPKC. In addition, KIBRA directly inhibits the kinase activity of aPKC in vitro. These results strongly support the notion that KIBRA regulates epithelial cell polarity by suppressing apical exocytosis through direct inhibition of aPKC kinase activity in the PAR3-aPKC-PAR6 complex.
Summary
Epithelial cells possess apical-basolateral polarity and form tight junctions (TJs) at the apical-lateral border, separating apical and basolateral membrane domains. The PAR3-aPKC-PAR6 complex plays a central role in TJ formation and apical domain development during tissue morphogenesis [1] [2] [3] [4] . Inactivation and overactivation of aPKC kinase activity disrupts membrane polarity [5] [6] [7] [8] . The mechanism that suppresses active aPKC is unknown. KIBRA, an upstream regulator of the Hippo pathway, regulates tissue size in Drosophila [9] [10] [11] and can bind to aPKC [12, 13] . However, the relationship between KIBRA and the PAR3-aPKC-PAR6 complex remains unknown. We report that KIBRA binds to the PAR3-aPKC-PAR6 complex and localizes at TJs and apical domains in epithelial tissues and cells. The knockdown of KIBRA causes expansion of the apical domain in MDCK three-dimensional cysts and suppresses the formation of apical-containing vacuoles through enhanced de novo apical exocytosis. These phenotypes are restored by inhibition of aPKC. In addition, KIBRA directly inhibits the kinase activity of aPKC in vitro. These results strongly support the notion that KIBRA regulates epithelial cell polarity by suppressing apical exocytosis through direct inhibition of aPKC kinase activity in the PAR3-aPKC-PAR6 complex.
Results and Discussion

KIBRA Interacts with the PAR3-aPKC-PAR6 Complex and Localizes at the Apical Domain in Mammalian Epithelial Cells
Previous studies on the direct interaction of KIBRA to aPKC [12, 13] suggest the involvement of KIBRA on epithelial cell polarity. To evaluate this possibility, we first examined its interaction with the PAR-aPKC complex. Immunoprecipitation experiments on ectopic proteins expressed in HEK293T cells ( Figure 1A ) as well as endogenous proteins in MDCK epithelial cells using an antibody raised against KIBRA ( Figure 1B ; Figure S1A available online) revealed that aPKC, PAR6b, and PAR3 coimmunoprecipitates with KIBRA. These results suggest that KIBRA can tightly associate with the PAR3-aPKC-PAR6 complex in epithelial cells.
The PAR3-aPKC-PAR6 complex localizes to TJs and the aPKC-PAR6 complex localizes to both TJ and apical domains in a variety of polarized epithelial cells and tissues including MDCK cells [5, [14] [15] [16] . Immunostaining of polarized MDCK monolayers revealed that KIBRA localizes to the cytoplasm and apical cell-cell junctions ( Figure 1C ; Figure S1B ). In MDCK cysts, the KIBRA staining clearly localizes at the apical domain and cell-cell junctions ( Figure 1D ). In the mouse kidney, KIBRA staining localizes at the apical cell-cell junctions of the distal tubular epithelium ( Figure 1E ; Figure S1C ). Thus, the localization of KIBRA in polarized epithelial cells is very similar to that of aPKC, supporting the notion that KIBRA is involved in epithelial cell polarization with the PAR3-aPKC-PAR6 complex.
KIBRA Suppresses Apical Domain Expansion during Cyst Formation
To evaluate the role of KIBRA on epithelial cell polarity, we established two independent MDCK cell clones with diminished KIBRA expression (KIBRA-kd1 and KIBRA-kd2). The expression of KIBRA was decreased to 10% ( Figure 2A ) and the apical and junctional staining of KIBRA was diminished in KIBRA-kd clones in both 2D and 3D cultures (Figures S1D and S1E), whereas the expression of other polarity proteins such as aPKC, PAR3, PAR6b, Lgl2, and PAR1b were not affected ( Figure 2A ).
We first assessed the involvement of KIBRA in the morphogenesis of cysts in a collagen gel. Compared with control cysts with a single and flat-surface apical lumen [7, 8] , the KIBRAkd1 clone generated cysts of peculiar morphology, where the apical domain of the cells in the cysts was expanded ( Figures 2B and 2C ). Another clone with a different target sequence, KIBRA-kd2, also generated cysts with the expanded apical domain ( Figures 2B and 2C) . Consistently, the expression of an apical marker protein, gp135/podocalyxin, was enhanced in KIBRA-kd clones (Figure 2A) . These results suggest a role for KIBRA in apical domain development of epithelial cells.
Recent studies in Drosophila revealed that Kibra acts as an activator of the Hippo pathway via interaction with the upstream regulators Merlin and Expanded through the N-terminal WW domains [9] [10] [11] . The Hippo pathway has previously been implicated in epithelial cell polarity control; epithelial cells of Drosophila Hippo pathway mutants display apical hypertrophy resulting from increased activation of the transcriptional coactivator protein Yorkie [17, 18] . These results suggest that KIBRA suppress apical development by activating the Hippo pathway. To evaluate this, we first confirmed that active mouse YAP1 (YAP1 S112A), whose Lats1/2-phosphorylation site was substituted to alanine [19] , induces apical expansion in MDCK cysts ( Figures S2A and S2B ). This suggests that YAP is involved in apical domain expansion not only in Drosophila but also in mammalian epithelial cells. We next examined the involvement of YAP in KIBRA knockdown-induced apical expansion via dominant-negative frequently formed smaller cysts and cell aggregates when embedded in collagen gels. However, dnYAP1 did not completely rescue the apical expansion phenotype in KIBRA-kd cysts ( Figures S2A and S2B ). Moreover, significant effects on the phosphorylation of YAP1 ( Figure S2C ) or the localization of YAP1 in cysts ( Figure S2D ) were not observed in KIBRA-kd clones. These results suggest that the apical expansion in KIBRA-kd cysts might involve unknown mechanisms in addition to YAP.
KIBRA Is Required for Formation of the Vacuolar Apical Compartment
To gain insight into the novel mechanisms that regulate epithelial polarity, we examined the phenotype of KIBRAkd clones in calcium switch (CS) and calcium depletion assays. Depletion of KIBRA did not show any significant defect in the recruitment of the TJ marker ZO-1 to the apical junction or transepithelial electrical resistance (TER) after a CS ( Figures S3A and  S3B ). These results show that KIBRA is not critically involved in cell-cell contact-dependent junction formation. Previous studies have established that in the absence of cell-cell contact, MDCK cells form a structure called the vacuolar apical compartment (VAC), where newly synthesized or endocytosed apical proteins accumulate [20, 21] . Genetic manipulation of the components of the PAR3-aPKC-PAR6 complex or Lgl affects VAC formation [7, 8] . Calcium depletion induced the appearance of VACs, aggregates of gp135 that costained with F-actin, in 50% of control cells as reported previously [7] . In contrast, VAC formation was almost completely suppressed in KIBRA-kd clones (Figures 3A and 3B; Figures S3C and S3D), similarly to Lgl1/2 knockdown [7] . These results indicate that KIBRA is required for the formation of the VAC under depolarized conditions, suggesting that KIBRA affects some step(s) of apical protein trafficking.
KIBRA Suppresses Exocytosis of Apical Membrane
The knockdown of Lgl1/2 suppresses VAC formation in depolarized MDCK cells as observed in KIBRA-kd clones [7] . Lgl-kd cells cultured in 2D showed resistance to apical domain internalization when the apical-free surface was overlaid with collagen gels ( Figure S3E ) [7] . However, KIBRA-kd cells showed internalization of apical proteins and formation of intercellular lumens in response to collagen overlay comparable to control clone, making a clear contrast to Lgl-kd cells ( Figure S3E ). These results suggest that KIBRA and Lgl regulate apical protein transport in a different manner.
KIBRA may suppress apical exocytosis to avoid apical expansion. To directly evaluate the role of KIBRA on the exocytosis of apical proteins, we traced the newly synthesized fusion protein of GFP and p75 neurotrophin receptor, a non-raft apical protein marker [22] . A tetracycline (Tet)-inducible (Tet-Off) p75-GFP adenovirus expression vector was used to induce p75-GFP expression after the cells were fully depolarized ( Figure 3C ). In the control cells with VACs, only a small proportion of p75-GFP was exocytosed to the cell surface. In KIBRAdepleted cells, which failed to form VACs, enhanced surface expression of p75-GFP was evident (Figures 3D and 3E; Figure S3F) . These results strongly support the notion that exocytosis of newly synthesized p75 is enhanced in KIBRA-kd clones, implicating the role of KIBRA in the suppression of apical protein exocytosis.
KIBRA Inhibits the Kinase Activity of aPKC Required for Apical Domain Development KIBRA binds directly to the kinase domain of aPKC [12, 13] . The sequence of the aPKC binding region in KIBRA (KIBRAaBR) is highly conserved among species, from Drosophila to humans, and contains a sequence similar to the pseudosubstrate (PS) of aPKC, suggesting a role in the regulation of aPKC kinase activity ( Figure 4A ). We purified Flag-tagged aPKC, KIBRA, and DC-KIBRA, which lacks the aPKC binding region ( Figure 4A ) [13] , from HEK293T cells ( Figure S4A ) and performed in vitro kinase assays. The purified KIBRA inhibited the activity of aPKC in a dose-dependent manner ( Figure 4B ; Table S1) in the presence of excessive amounts of the substrate, myelin basic protein (MBP; approximately 10 mM). However, this inhibition was not observed for DC-KIBRA (Figure 4B ; Table S1 ). A Lineweaver-Burk plot demonstrated that KIBRA inhibited aPKC in a competitive manner ( Figure 4C ; Table S2 ) and a Dixon plot showed that the Ki value was 2-3 nM ( Figure 4D ). Furthermore, purified GST-tagged KIBRA-aBR ( Figure S4A ) also inhibited the kinase activity of aPKC in a dose-dependent manner and its inhibition was competitive (Figures S4B and S4C ; Tables S1 and S2). These results clearly establish that KIBRA directly binds to aPKC and inhibits its kinase activity in a cell-free system.
Next, we investigated whether the interaction between aPKC and KIBRA is required for apical development. The apical expansion phenotype in the KIBRA-kd1 clone was almost completely suppressed by the re-expression of EGFP-KIBRA, and the re-expression of DC-KIBRA did not completely rescue the phenotype (Figures 4E-4G) . These results suggest that the C-terminal region of KIBRA is required for suppression of apical development. We also examined whether KIBRA-aBR was sufficient for aPKC inhibition to suppress apical development by overexpressing tRFP-tagged KIBRA-aBR (tRFP-KIBRA-aBR) in wild-type MDCK cells. As expected, the overexpression of tRFP-KIBRA-aBR increased the occurrence of VAC formation, which is similar to aPKC inhibition ( Figures S4D and S4G) . We confirmed the interaction between endogenous aPKC and tRFP-KIBRA-aBR in the cytoplasm (data not shown), although tRFP-KIBRA-aBR exhibited relatively strong nuclear localization by immunofluorescence ( Figure S4D ). These results are consistent with the notion that KIBRA suppresses apical domain development by directly inhibiting the kinase activity of aPKC.
To obtain further evidence supporting the involvement of the interaction between KIBRA and aPKC, we next examined whether the phenotypes observed in KIBRA-kd clones were rescued by inhibition of the kinase activity of aPKC. The KIBRA-kd clones treated with aPKC inhibitor exhibited increased VAC formation in a dose-dependent manner ( Figures  S4E and S4H) . Furthermore, apical expansion phenotype in KIBRA-kd cysts were partially rescued by treatment with 20 mM aPKC inhibitor, which did not affect normal cyst formation in control clone ( Figures S4F and S4I) . These results strongly support the notion that the increased apical domain development in KIBRA-kd clones were caused by upregulation of aPKC kinase activity.
KIBRA Is a Negative Regulator of aPKC during Apical Development
Previous studies have demonstrated that KIBRA directly binds to and is phosphorylated by aPKC, suggesting that KIBRA is a scaffold protein or a phosphorylation target that mediates aPKC activity to the downstream events [12, 23] . However, the knockdown of KIBRA did not affect TJ formation during cell-cell contact-dependent polarization ( Figures S3A and  S3B) , showing a clear contrast to the cells in which aPKC activity was inhibited [5, 24] . Rather, KIBRA knockdown phenotype shows apical expansion in cysts ( Figure 2 ) and increased apical exocytosis (Figure 3 ), suggesting that KIBRA knockdown causes enhanced aPKC activity, which is required for apical domain development [7, 8, 25] . Consistently, the abnormal phenotypes of KIBRA-kd clones were substantially reverted by inhibiting aPKC activity ( Figure S4 ). Furthermore, KIBRA exhibited competitive inhibitory activity on aPKC kinase activity in vitro through its aPKC binding region. We also confirmed that the aBR domain is sufficient and required for KIBRA activity to regulate apical domain development (Figure 4 ). These observations support the notion that KIBRA acts as a negative regulator of aPKC activity in apical domain development. The apical expansion in MDCK cysts that was observed for KIBRA-kd clones were similar to that observed for cells overexpressing Crumbs3, which localizes to the apical domain and cooperates with the PAR complex for apical domain development [26] [27] [28] [29] . In Drosophila, Crumbs phosphorylation by aPKC has been shown to be crucial for its function [30] . Therefore, KIBRA may inhibit apical domain development by inhibiting Crumbs3 phosphorylation through aPKC. However, we observed that overexpression of human Crumbs3 T89/ 92A, with two threonine residues corresponding to aPKC phosphorylation sites in Drosophila altered to alanine residues [30] , did not suppress the apical expansion phenotype in KIBRA-kd clones (data not shown). This suggests the presence of additional unknown aPKC target(s) inhibited by KIBRA during apical development. Recent studies suggest that aPKC activity is required for mediating exocyst-dependent apical vesicle docking to the PAR3-localizing site [8, 25] . Another study suggested that KIBRA interacts with the exocyst complex during directional migration of podocytes [31] . In this work, we demonstrated that KIBRA knockdown upregulated apical protein exocytosis (Figures 3C-3E) . Taken together, KIBRA may suppress apical vesicle docking to the PAR3-localizing site through inhibition of aPKC kinase activity.
Conclusion
In this study, we provided evidence indicating that KIBRA negatively regulates epithelial cell polarity by suppressing aPKC kinase activity in the PAR-aPKC polarity complex through its short C-terminal aPKC binding sequence. Our results further indicate that this inhibitory effect of KIBRA on aPKC mediates suppression of apical exocytosis, a process implicated in the development of the apical domain and hence epithelial cell polarity.
Experimental Procedures
Cell Culture and Transfection MDCK and HEK293T cells were cultured in DMEM supplemented with 10% FBS and 100 U/ml penicillin and streptomycin (GIBCO-BRL) at 37 C/5% CO 2 . Cells were transfected with Lipofectamine 2000 (Invitrogen) or Nucleofector (Amaxa) with appropriate plasmids. KIBRA knockdown MDCK cell clones were established by transfection with pSUPER-puro encoding KIBRA shRNA sequences (5 0 -GGTACAACCTCCTAAGCTA-3 0 for KIBRA-kd1 and 5
0 -GGTTGGAGATTACTTCATA-3 0 for KIBRA-kd2) and selection with 2 mg/ml puromycin. Control clones were established similarly with a nonsilencing sequence (5 0 -CAGTCGCGTTTGCGACTGG-3 0 ). The mLgl1/2 doubleknockdown MDCK clone (24-15) was established previously [7] . Rescue clones were established by transfection with the RNAi-resistant mouse homolog of KIBRA. The pEGFP-C2, pEGFP-KIBRA, or pEGFP-DC-KIBRA vectors were transfected into KIBRA-kd1 clone and selected with 800 mg/ml G418. The control rescue clone was established similarly by transfection and selection with the pEGFP-C2 vector and nonsilencing control clones.
Cyst Formation MDCK cell cyst formation was performed as described previously [7] . Cysts were fixed with 2% PFA/PBS for 30 min, permeabilized with 0.5% Triton X-100/PBS for 30 min at room temperature, and immunostained as previously described [32] .
Evaluation of the Exocytosis of Newly Synthesized p75-GFP to the Cell Surface Confluent monolayers of stable clones were washed twice with PBS containing 0.02% EDTA and then incubated in LC medium for 2 hr. Cells were then incubated with LC medium containing 2.5 3 10 7 pfu/ml of Tet-inducible p75-GFP adenovirus expression vector for 2 hr. After infection, cells were incubated in LC medium with 20 ng/ml doxycycline for more than 20 hr. Cells were washed twice with PBS and then incubated in LC medium for a further 8 hr to allow for the expression of p75-GFP. Cells were fixed with 0.2% PFA/ PBS for 15 min at room temperature and blocked with 10% calf serum in PBS for 30 min at room temperature. Surface p75-GFP was then labeled with mouse anti-NGFR monoclonal antibody (Chemicon, 8211), which recognizes the ectodomain of human p75 [33] . After surface labeling, cells were refixed with 4% PFA/PBS for 15 min at room temperature, permeabilized with 0.5% Triton X-100/PBS for 10 min at room temperature, and reblocked with 10% calf serum in PBS. To enhance the signal intensity of GFP, cells were incubated with chicken anti-EGFP antibody (Aves Labs), which resulted in the labeling of total p75-GFP. Samples were then incubated with Alexa 488-conjugated anti-chicken IgG and Alexa 555-conjugated anti-mouse IgG antibodies, as well as Alexa 647-conjugated phalloidin.
To quantify the rate of surface incorporation of newly synthesized p75-GFP, cells were randomly selected from samples, and the average signal intensity of surface p75-GFP (Alexa 555) and that of total p75-GFP (GFP) was measured with ImageJ software. The average score of the resulting ratio (surface p75/ total p75) from nonsilencing control cells was designated as 1 for each experiment, and the relative exocytosis rate was calculated for all selected cells.
In Vitro Kinase Assays PKC activity was measured in vitro by a standard vesicle assay with MBP as a substrate, as described previously [34] . The incorporation of 32 P with MBP was determined by Cerenkov counting. The values for control reactions (D) Dixon plot of the MBP phosphorylation by aPKCz in the presence of KIBRA. Two different straight lines with 100 mg/ml (gray circle) or 400 mg/ml (black diamond) of MBP, respectively, intersected at a point beyond the vertical axis. A perpendicular line dropped from the point of intersection on the horizontal axis yielded the value of Ki. Each data point demonstrates the results of three independent experiments. (E) Lysates derived from rescue clones were subjected to immunoblotting with the antibodies indicated. Blotting for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. (F) Rescue clones were cultured in type I collagen gel for 5 days, then stained for GFP (green), F-actin (red), and ZO-1 (blue). Scale bar represents 10 mm. (G) More than 100 cysts were counted and categorized, and the percentage of the cyst in each category was calculated. Values represent the mean 6 SD of three independent experiments. *p < 0.05 by one way-ANOVA, Turkey's test. See also Figure S4 and Tables S1 and S2. lacking the substrate were subtracted as blanks. Phosphorylation efficiency (pmol/min) was calculated by comparing the obtained count to Cerenkov counting for 10 pmol of ATP mixture.
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